Literature DB >> 21668011

Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4.

Marilena Manea1, Ulrike Leurs, Erika Orbán, Zsuzsa Baranyai, Peter Öhlschläger, Andreas Marquardt, Ákos Schulcz, Miguel Tejeda, Bence Kapuvári, József Tóvári, Gábor Mezo.   

Abstract

Here, we report on the synthesis, enzymatic stability, and antitumor activity of novel bioconjugates containing the chemotherapeutic agent daunorubicin attached through an oxime bond to various gonadotropin-releasing hormone-III (GnRH-III) derivatives. In order to increase the enzymatic stability of the bioconjugates (in particular against chymotrypsin), (4)Ser was replaced by N-Me-Ser or Lys(Ac). A compound in which (4)Lys was not acetylated was also prepared, with the aim of investigating the influence of the free ε-amino group on the biochemical properties. The in vitro cytostatic effect of the bioconjugates was determined on MCF-7 human breast, HT-29 human colon, and LNCaP human prostate cancer cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Their stability/degradation (1) in human serum, (2) in the presence of rat liver lysosomal homogenate, and (3) in the presence of digestive enzymes (trypsin, chymotrypsin, and pepsin) was analyzed by liquid chromatography in combination with mass spectrometry. The results showed that (1) all synthesized bioconjugates had in vitro cytostatic effect, (2) they were stable in human serum at least for 24 h, and (3) they were hydrolyzed in the presence of lysosomal homogenate. All compounds were stable in the presence of (1) pepsin and (2) trypsin (except for the (4)Lys containing bioconjugate). In the presence of chymotrypsin, all bioconjugates were digested; the degradation rate strongly depending on their structure. The bioconjugates in which (4)Ser was replaced by N-Me-Ser or Lys(Ac) had the highest enzymatic stability, making them potential candidates for oral administration. In vivo tumor growth inhibitory effect of two selected bioconjugates was evaluated on orthotopically developed C26 murine colon carcinoma bearing mice. The results indicated that the compound containing Lys(Ac) in position 4 had significantly higher antitumor activity than the parent bioconjugate.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21668011     DOI: 10.1021/bc100547p

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  11 in total

1.  Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.

Authors:  S Torok; A Vegvari; M Rezeli; T E Fehniger; J Tovari; S Paku; V Laszlo; B Hegedus; A Rozsas; B Dome; G Marko-Varga
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

2.  Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates.

Authors:  Sabine Schuster; Éva Juhász; Gábor Halmos; Ines Neundorf; Cesare Gennari; Gábor Mező
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 6.208

3.  Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugate.

Authors:  Verena Natalie Schreier; Lilla Pethő; Erika Orbán; Andreas Marquardt; Brindusa Alina Petre; Gábor Mező; Marilena Manea
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

4.  Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.

Authors:  Ivan Ranđelović; Sabine Schuster; Bence Kapuvári; Gianluca Fossati; Christian Steinkühler; Gábor Mező; József Tóvári
Journal:  Int J Mol Sci       Date:  2019-09-25       Impact factor: 5.923

5.  Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.

Authors:  Bence Kapuvári; Rózsa Hegedüs; Ákos Schulcz; Marilena Manea; József Tóvári; Alexandra Gacs; Borbála Vincze; Gábor Mező
Journal:  Invest New Drugs       Date:  2016-05-05       Impact factor: 3.850

6.  Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.

Authors:  Sabine Schuster; Beáta Biri-Kovács; Bálint Szeder; Viktor Farkas; László Buday; Zsuzsanna Szabó; Gábor Halmos; Gábor Mező
Journal:  Beilstein J Org Chem       Date:  2018-04-04       Impact factor: 2.883

Review 7.  On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.

Authors:  Eirinaios I Vrettos; Gábor Mező; Andreas G Tzakos
Journal:  Beilstein J Org Chem       Date:  2018-04-26       Impact factor: 2.883

8.  Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids.

Authors:  Eszter Lajkó; Sarah Spring; Rózsa Hegedüs; Beáta Biri-Kovács; Sven Ingebrandt; Gábor Mező; László Kőhidai
Journal:  Beilstein J Org Chem       Date:  2018-09-26       Impact factor: 2.883

9.  Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells.

Authors:  Gábor Mező; László Kőhidai; Livia Polgár; Eszter Lajkó; Pál Soós; Orsolya Láng; Marilena Manea; Béla Merkely
Journal:  Beilstein J Org Chem       Date:  2018-06-28       Impact factor: 2.883

10.  Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells.

Authors:  Eszter Lajkó; Rózsa Hegedüs; Gábor Mező; László Kőhidai
Journal:  Int J Mol Sci       Date:  2019-09-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.